Press Release

Cell & Gene Therapy Cold Chain Logistics Market to Grow with a CAGR of 6.19% through 2028

Rising Clinical Trials Approvals are expected to drive the Germany Cell & Gene Therapy Cold Chain Logistics Market growth in the forecast period, 2024-2028.

 

 According to TechSci Research report, “Cell & Gene Therapy Cold Chain Logistics Market – Germany Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Germany Cell & Gene Therapy Cold Chain Logistics Market stood at USD 107.51 million in 2022 and is anticipated to grow with a CAGR of 13.87% in the forecast period, 2024-2028. Germany has been at the forefront of cell and gene therapy research and development. The country's renowned pharmaceutical and biotechnology industry has been instrumental in driving innovation in this field. As more breakthrough therapies are developed, the need for a robust cold chain logistics system becomes increasingly evident. These therapies often involve fragile and temperature-sensitive materials, making specialized logistics essential to maintain their efficacy. Germany is witnessing a surge in clinical trials and approvals for cell and gene therapies. With an emphasis on precision medicine and personalized treatments, the demand for secure transportation of patient-specific therapies is on the rise. The cold chain logistics market is benefiting from this trend, as it must provide specialized services to ensure the safe delivery of these therapies from manufacturing facilities to healthcare providers.

The rapid evolution of technology is driving innovation in the cold chain logistics market. Advanced temperature monitoring systems, IoT (Internet of Things) solutions, and data analytics are becoming integral to ensuring the integrity of cell and gene therapy products during transportation. These technologies are not only improving the safety and efficiency of logistics but also reducing costs, making them more attractive to industry players.

Regulatory bodies in Germany, such as the Federal Institute for Drugs and Medical Devices (BfArM), and the European Medicines Agency (EMA), have established strict guidelines for the transportation and storage of cell and gene therapy products. Compliance with these regulations is non-negotiable, and logistics providers must adhere to them to ensure product safety and efficacy. This emphasis on compliance has boosted the demand for specialized cold chain logistics services. Both public and private investments are flowing into the cell and gene therapy sector in Germany. Funding is being directed towards research, development, and the expansion of manufacturing facilities. With more therapies entering the pipeline, the demand for cold chain logistics is rising in tandem. Investors recognize the potential of this market and are actively supporting its growth.

 

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Germany Cell & Gene Therapy Cold Chain Logistics Market.”

 

Germany has emerged as a popular destination for dental tourism, attracting patients from across Europe and beyond. The country's high-quality dental care, well-trained professionals, and advanced dental facilities have made it an attractive choice for individuals seeking dental treatments. Dental tourism has resulted in a higher influx of patients, leading to increased demand for Cell & Gene Therapy Cold Chain Logistics in German dental clinics and hospitals.

The Germany Cell & Gene Therapy Cold Chain Logistics Market is segmented into Component, Services Offered, Mode of Transportation, Holding Temperature Range, End User, Regional Distribution, And Company.

Based on the Component, Cryogenic Shippers emerged as the dominant segment in the North America market for Germany Cell & Gene Therapy Cold Chain Logistics Market in 2022. irst cell and gene therapies often involve the transportation of extremely fragile and temperature-sensitive biological materials, such as living cells, viral vectors, or nucleic acids. These materials must be stored and transported at ultra-low temperatures, typically in the range of -80°C to -196°C, to maintain their stability and efficacy. Cryogenic shippers, which utilize liquid nitrogen or other cryogenic agents, provide the necessary extreme cold conditions for the secure transport of these therapies. the stringent regulatory guidelines enforced by entities like the Federal Institute for Drugs and Medical Devices (BfArM) and the European Medicines Agency (EMA) necessitate the use of highly reliable and validated temperature-controlled systems. Cryogenic shippers have proven themselves as reliable and well-established solutions that meet the stringent temperature control requirements set forth by these regulatory bodies.

Based on the Holding Temperature Range, the Cryogenic segment emerged as the dominant player in the North America market for Germany Cell & Gene Therapy Cold Chain Logistics Market in 2022. First and foremost, cell and gene therapies often involve the transport and storage of extremely delicate and temperature-sensitive biological materials, including living cells, viral vectors, and nucleic acids. These materials require ultra-low temperatures to maintain their stability and effectiveness, typically within the range of -80°C to -196°C. Cryogenic holding temperature ranges, which utilize liquid nitrogen or other cryogenic agents, provide the ideal conditions for ensuring the safe preservation of these therapies throughout the supply chain.Additionally, the stringent regulatory requirements imposed by entities such as the Federal Institute for Drugs and Medical Devices (BfArM) and the European Medicines Agency (EMA) demand the highest level of temperature control and stability. Cryogenic storage solutions have demonstrated their reliability in maintaining these stringent temperature standards, making them a preferred choice for complying with regulatory guidelines.The rising number of clinical trials and approvals for cell and gene therapies in Germany further accentuates the importance of cryogenic holding temperature ranges. These trials often involve patient-specific therapies that require precise temperature control and stability to ensure their safety and efficacy. Cryogenic systems offer the most secure and dependable means of achieving these critical temperature conditions.

Based on the Services Offered, the Transportation segment emerged as the dominant player in the North America market for Germany Cell & Gene Therapy Cold Chain Logistics Market in 2022. cell and gene therapies often involve the transportation of highly delicate and temperature-sensitive biological materials, such as living cells, viral vectors, and nucleic acids. Maintaining the required temperature conditions throughout the transportation process is critical to preserving the integrity and efficacy of these therapies. Transportation services are at the forefront of achieving this, as they are responsible for physically moving these products from manufacturing facilities to research institutions, healthcare providers, or directly to patients. the Germany Cell & Gene Therapy Cold Chain Logistics Market has experienced a surge in clinical trials and approvals for these innovative therapies. Clinical trials frequently require the transportation of patient-specific therapies, demanding precise, secure, and timely delivery. Transportation services offer specialized expertise, equipped vehicles, and temperature-controlled containers that ensure the therapies arrive in pristine condition.

Western region emerged as the dominant player in the Germany Cell & Gene Therapy Cold Chain Logistics Market in 2022, holding the largest market share. Western Germany is home to major cities such as Frankfurt, Düsseldorf, and Cologne, which have established themselves as biotech and pharmaceutical hubs. These cities host numerous research institutions, pharmaceutical companies, and biotechnology firms engaged in cutting-edge cell and gene therapy research and development. The concentration of these organizations in the Western region results in a higher demand for logistics services to support their activities. The Western region boasts a strong and diverse economy, making it a favorable location for investment and innovation in the life sciences sector. The economic strength of this region enables it to attract significant investments in research and clinical trials related to cell and gene therapies. As these therapies progress, the demand for cold chain logistics services for transportation and storage naturally surges

 

Major companies operating in Germany Cell & Gene Therapy Cold Chain Logistics Market are:

  • AmerisourceBergen Corporation (World Courier)
  • United Parcel Service (Marken)
  • Catalent, Inc.
  • BioLife Solutions, Inc.
  • Cryoport, Inc.
  • Atelerix Ltd.
  • Biostor Ltd.
  • Thermo Fisher Scientific Inc.
  • Life Science Group Ltd (LSG)
  • Yourway Biopharma Services Company

 

Download Free Sample Report

Customers can also request for 10% free customization on this report.

 

 “The Germany Cell & Gene Therapy Cold Chain Logistics Market is poised for significant growth in the coming years. Anticipated advancements in cell and gene therapies, along with a robust clinical trials pipeline, will continue to drive demand for precise and temperature-controlled logistics services. Germany's position as a leader in biotechnology and pharmaceutical research further reinforces its role as a key player in the development and distribution of these innovative therapies.The rising number of clinical trials and approvals by regulatory bodies such as the Federal Institute for Drugs and Medical Devices (BfArM) and the European Medicines Agency (EMA) underscores the industry's increasing recognition and acceptance. As these therapies transition from experimental to mainstream treatments, the importance of secure and compliant cold chain logistics becomes even more evident.” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Germany Cell & Gene Therapy Cold Chain Logistics Market Segmented By Component (Cryogenic Shippers, Cryogenic Storage Freezers, Ultra Low Freezers, Cold Chain Management Systems, Shipment and Storage Medium, Cryogenic Packout Kits Others {Shipment Containers, Reusable Boxes, etc.}), By Services Offered (Transportation, Storage, Packaging) , By Mode of Transportation (Air, Ground, Water) , By  Holding Temperature Range (Cryogenic, Refrigerated, Ambient, Others {Deep Freezers, Dry Ice, etc.}) , By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others) Region and Competition, Opportunity, and Forecast, 2018-2028”, has evaluated the future growth potential of Germany Cell & Gene Therapy Cold Chain Logistics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Germany Cell & Gene Therapy Cold Chain Logistics Market.

 

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com

Relevant News